{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:28:37Z","timestamp":1784690917134,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Top Talent of Changzhou \u201cThe 14th Five-Year Plan\u201d High-Level Health Talents Training Project","award":["2022CZBJ086"],"award-info":[{"award-number":["2022CZBJ086"]}]},{"name":"Applied Basic Research Program of Changzhou Science and Technology Bureau","award":["CJ20230077"],"award-info":[{"award-number":["CJ20230077"]}]},{"name":"Zhejiang Provincial Medical and Health Program","award":["2025KY985"],"award-info":[{"award-number":["2025KY985"]}]},{"DOI":"10.13039\/501100004863","name":"Zhejiang Chinese Medical University","doi-asserted-by":"crossref","award":["2022FSYYZZ11"],"award-info":[{"award-number":["2022FSYYZZ11"]}],"id":[{"id":"10.13039\/501100004863","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This exploratory survey study aimed to evaluate the epidemiology, treatment patterns (including pharmacotherapy, rehabilitation, and supportive care), economic burden, drug preferences, and unmet needs of Chinese SMA patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted an anonymous online survey using a self-developed questionnaire from March 4 to March 31, 2024. The questionnaire collected comprehensive data on epidemiology, treatment patterns, rehabilitative interventions, nursing management, economic burden, and preferences. Data analysis was performed using descriptive statistics and chi-square tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Analysis of 82 valid questionnaires revealed that 91.5% of SMA patients had type I or II disease, with 69.5% diagnosed by genetic testing within 12 months of birth. Awareness of prenatal screening was low. Nusinersen and Risdiplam showed comparable utilization rates and efficacy, though Risdiplam was associated with significantly higher rates of adverse events. Over 75% of caregivers reported financial constraints, with more than 42% expressing long-term affordability concerns. Rehabilitation participation reached 86.6%, predominantly involving motor function training, stretching therapy, and the use of assistive devices. Critical gaps included the finding that 89.0% of caregivers lacked formal training, 40.8% of patients lacking respiratory interventions, and a high demand for emergency skills training (61.0%). Treatment preferences prioritized oral administration, liquid formulations, and fruit flavors, with efficacy, affordability, and ease of use (80.5%) being the primary decision-driving factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The management of SMA in China faces three primary challenges: inadequate prevention awareness, critical caregiving deficiencies, and prohibitively high treatment costs. Urgent actions include scaling up prenatal\/newborn screening, establishing multidisciplinary care models to address respiratory\/nutritional gaps, and implementing policy reforms to improve affordable drug access.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-026-04774-z","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T09:35:14Z","timestamp":1772184914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world treatment patterns and unmet needs in spinal muscular atrophy: a caregiver-centric survey study from China"],"prefix":"10.1186","volume":"26","author":[{"given":"Wenxiang","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Er","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoqing","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingping","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"4774_CR1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","volume":"8 1","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS. Spinal muscular atrophy. Nat Rev Dis Primers. 2022;8 1:52. https:\/\/doi.org\/10.1038\/s41572-022-00380-8.","journal-title":"Nat Rev Dis Primers"},{"key":"4774_CR2","doi-asserted-by":"publisher","unstructured":"Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis. 2017;12(1:124). https:\/\/doi.org\/10.1186\/s13023-017-0671-8.","DOI":"10.1186\/s13023-017-0671-8"},{"key":"4774_CR3","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00415-017-8549-1","volume":"264 7","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, Robertson A, Leary R, McMacken G, Konig K, Kirschner J, et al. A multi-source approach to determine SMA incidence and research ready population. J Neurol. 2017;264 7:1465\u201373. https:\/\/doi.org\/10.1007\/s00415-017-8549-1.","journal-title":"J Neurol"},{"key":"4774_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ejhg.2011.134","volume":"20 1","author":"EA Sugarman","year":"2012","unstructured":"Sugarman EA, Nagan N, Zhu H, Akmaev VR, Zhou Z, Rohlfs EM, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >\u200972,400 specimens. Eur J Hum Genet. 2012;20 1:27\u201332. https:\/\/doi.org\/10.1038\/ejhg.2011.134.","journal-title":"Eur J Hum Genet"},{"key":"4774_CR5","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.3389\/fgene.2019.01255","volume":"10","author":"Y Lin","year":"2019","unstructured":"Lin Y, Lin CH, Yin X, Zhu L, Yang J, Shen Y, et al. Newborn Screening for Spinal Muscular Atrophy in China Using DNA Mass Spectrometry. Front Genet. 2019;10:1255. https:\/\/doi.org\/10.3389\/fgene.2019.01255.","journal-title":"Front Genet"},{"key":"4774_CR6","doi-asserted-by":"publisher","first-page":"e18975","DOI":"10.1097\/MD.0000000000018975","volume":"99 5","author":"C Li","year":"2020","unstructured":"Li C, Geng Y, Zhu X, Zhang L, Hong Z, Guo X, et al. The prevalence of spinal muscular atrophy carrier in China: Evidences from epidemiological surveys. Med (Baltim). 2020;99 5:e18975. https:\/\/doi.org\/10.1097\/MD.0000000000018975.","journal-title":"Med (Baltim)"},{"key":"4774_CR7","doi-asserted-by":"publisher","unstructured":"Day JW, Howell K, Place A, Long K, Rossello J, Kertesz N, et al. Advances and limitations for the treatment of spinal muscular atrophy. BMC Pediatr. 2022;22(1:632). https:\/\/doi.org\/10.1186\/s12887-022-03671-x.","DOI":"10.1186\/s12887-022-03671-x"},{"key":"4774_CR8","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377 18","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med. 2017;377 18:1723\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1702752.","journal-title":"N Engl J Med"},{"key":"4774_CR9","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/S1474-4422(22)00339-8","volume":"21 12","author":"R Masson","year":"2022","unstructured":"Masson R, Mazurkiewicz-Beldzinska M, Rose K, Servais L, Xiong H, Zanoteli E, et al. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial. Lancet Neurol. 2022;21 12:1110\u20139. https:\/\/doi.org\/10.1016\/S1474-4422(22)00339-8.","journal-title":"Lancet Neurol"},{"key":"4774_CR10","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20 4","author":"JW Day","year":"2021","unstructured":"Day JW, Finkel RS, Chiriboga CA, Connolly AM, Crawford TO, Darras BT, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20 4:284\u201393. https:\/\/doi.org\/10.1016\/S1474-4422(21)00001-6.","journal-title":"Lancet Neurol"},{"key":"4774_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S1474-4422(23)00419-2","volume":"23 2","author":"CJJ Yeo","year":"2024","unstructured":"Yeo CJJ, Tizzano EF, Darras BT. Challenges and opportunities in spinal muscular atrophy therapeutics. Lancet Neurol. 2024;23 2:205\u201318. https:\/\/doi.org\/10.1016\/S1474-4422(23)00419-2.","journal-title":"Lancet Neurol"},{"key":"4774_CR12","doi-asserted-by":"publisher","unstructured":"Zhao M, Ding S, Zhao Y, Lin C, Han Y. Healthcare Resource Utilization, Economic Burden, and Multi-Level Medical Security System for Individuals with Spinal Muscular Atrophy in Shaanxi Province, China. Healthc (Basel). 2025;13(4). https:\/\/doi.org\/10.3390\/healthcare13040428.","DOI":"10.3390\/healthcare13040428"},{"key":"4774_CR13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2102047","volume":"385 5","author":"BT Darras","year":"2021","unstructured":"Darras BT, Masson R, Mazurkiewicz-Beldzinska M, Rose K, Xiong H, Zanoteli E, et al. Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls. N Engl J Med. 2021;385 5:427\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2102047.","journal-title":"N Engl J Med"},{"key":"4774_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpn.2022.04.006","volume":"39","author":"J Erdos","year":"2022","unstructured":"Erdos J, Wild C. Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data. Eur J Paediatr Neurol. 2022;39:1\u201310. https:\/\/doi.org\/10.1016\/j.ejpn.2022.04.006.","journal-title":"Eur J Paediatr Neurol"},{"issue":"2","key":"4774_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28(2):103\u201315. https:\/\/doi.org\/10.1016\/j.nmd.2017.11.005.","journal-title":"Neuromuscul Disord"},{"key":"4774_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.31083\/j.fbl2706179","volume":"27 6","author":"A Mirea","year":"2022","unstructured":"Mirea A, Leanca MC, Onose G, Sporea C, Padure L, Shelby ES, et al. Physical Therapy and Nusinersen Impact on Spinal Muscular Atrophy Rehabilitative Outcome. Front Biosci (Landmark Ed). 2022;27 6:179. https:\/\/doi.org\/10.31083\/j.fbl2706179.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"4774_CR17","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s12325-024-03101-7","volume":"42 4","author":"X Zhao","year":"2025","unstructured":"Zhao X, Liao Y, Zhao J, Zhu L, Liu J, Zhang M, et al. Motor Function and Safety of Nusinersen and Risdiplam in Asian Patients with Types 2\u20134 Spinal Muscular Atrophy (SMA): A Systematic Review and Meta-Analysis. Adv Ther. 2025;42 4:1611\u201326. https:\/\/doi.org\/10.1007\/s12325-024-03101-7.","journal-title":"Adv Ther"},{"key":"4774_CR18","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/mus.27116","volume":"63 3","author":"E Chen","year":"2021","unstructured":"Chen E, Dixon S, Naik R, Noone JM, Buchenberger JD, Whitmire SM, et al. Early experiences of nusinersen for the treatment of spinal muscular atrophy: Results from a large survey of patients and caregivers. Muscle Nerve. 2021;63 3:311\u20139. https:\/\/doi.org\/10.1002\/mus.27116.","journal-title":"Muscle Nerve"},{"key":"4774_CR19","doi-asserted-by":"publisher","unstructured":"Rovira-Moreno E, Abuli A, Munoz-Cabello P, Codina-Sola M, Bailles E, de Lemus M, et al. The diagnosis communication process in spinal muscular atrophy: A cross-cutting view of the new challenges facing the therapeutic era. Genet Med Open. 2023;1(1:100825). https:\/\/doi.org\/10.1016\/j.gimo.2023.100825.","DOI":"10.1016\/j.gimo.2023.100825"},{"key":"4774_CR20","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3760\/cma.j.cn112140-20220315-00201","volume":"60 9","author":"Subspecialty Group of Rehabilitation tSoPCMA, Physical Therapy Committee of Chinese Association of Rehabilitation M","year":"2022","unstructured":"Subspecialty Group of Rehabilitation tSoPCMA, Physical Therapy Committee of Chinese Association of Rehabilitation M. [Expert consensus on rehabilitation management of the spinal muscular atrophy]. Zhonghua Er Ke Za Zhi. 2022;60 9:883\u20137. https:\/\/doi.org\/10.3760\/cma.j.cn112140-20220315-00201.","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"4774_CR21","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1053\/j.ajkd.2023.11.005","volume":"83 6","author":"TK Novick","year":"2024","unstructured":"Novick TK, Osuna M, Emery C, Barrios F, Ramirez D, Crews DC, et al. Patients\u2019 Perspectives on Health-Related Social Needs and Recommendations for Interventions: A Qualitative Study. Am J Kidney Dis. 2024;83 6:739\u201349. https:\/\/doi.org\/10.1053\/j.ajkd.2023.11.005.","journal-title":"Am J Kidney Dis"},{"key":"4774_CR22","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.nmd.2021.03.007","volume":"31 6","author":"T Dangouloff","year":"2021","unstructured":"Dangouloff T, Vrscaj E, Servais L, Osredkar D, Group SNWS. Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go. Neuromuscul Disord. 2021;31 6:574\u201382. https:\/\/doi.org\/10.1016\/j.nmd.2021.03.007.","journal-title":"Neuromuscul Disord"},{"key":"4774_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/ijms241511939","volume":"24","author":"H Nishio","year":"2023","unstructured":"Nishio H, Niba ETE, Saito T, Okamoto K, Takeshima Y, Awano H. Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment. Int J Mol Sci. 2023;24:15. https:\/\/doi.org\/10.3390\/ijms241511939.","journal-title":"Int J Mol Sci"},{"key":"4774_CR24","doi-asserted-by":"publisher","first-page":"8978","DOI":"10.1001\/jamaneurol.2019.1206","volume":"76","author":"M Baker","year":"2019","unstructured":"Baker M, Griggs R, Byrne B, Connolly AM, Finkel R, Grajkowska L, et al. Maximizing the Benefit of Life-Saving Treatments for Pompe Disease, Spinal Muscular Atrophy, and Duchenne Muscular Dystrophy Through Newborn Screening: Essential Steps. JAMA Neurol. 2019;76:8978\u201383. https:\/\/doi.org\/10.1001\/jamaneurol.2019.1206.","journal-title":"JAMA Neurol"},{"key":"4774_CR25","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/gim.2017.152","volume":"20 6","author":"JN Kraszewski","year":"2018","unstructured":"Kraszewski JN, Kay DM, Stevens CF, Koval C, Haser B, Ortiz V, et al. Pilot study of population-based newborn screening for spinal muscular atrophy in New York state. Genet Med. 2018;20 6:608\u201313. https:\/\/doi.org\/10.1038\/gim.2017.152.","journal-title":"Genet Med"},{"issue":"1","key":"4774_CR26","doi-asserted-by":"publisher","first-page":"e200224","DOI":"10.1212\/CPJ.0000000000200224","volume":"14","author":"VD Armengol","year":"2024","unstructured":"Armengol VD, Darras BT, Abulaban AA, Alshehri A, Barisic N, Ben-Omran T, et al. Life-Saving Treatments for Spinal Muscular Atrophy: Global Access and Availability. Neurol Clin Pract. 2024;14(1):e200224. https:\/\/doi.org\/10.1212\/CPJ.0000000000200224.","journal-title":"Neurol Clin Pract"},{"key":"4774_CR27","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1017\/cjn.2020.229","volume":"48 4","author":"HJ McMillan","year":"2021","unstructured":"McMillan HJ, Kernohan KD, Yeh E, Amburgey K, Boyd J, Campbell C, et al. Newborn Screening for Spinal Muscular Atrophy: Ontario Testing and Follow-up Recommendations. Can J Neurol Sci. 2021;48 4:504\u201311. https:\/\/doi.org\/10.1017\/cjn.2020.229.","journal-title":"Can J Neurol Sci"},{"key":"4774_CR28","doi-asserted-by":"publisher","unstructured":"Boemer F, Caberg JH, Beckers P, Dideberg V, di Fiore S, Bours V, et al. Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium. Sci Rep. 2021;11(1:19922). https:\/\/doi.org\/10.1038\/s41598-021-99496-2.","DOI":"10.1038\/s41598-021-99496-2"},{"key":"4774_CR29","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.nmd.2020.10.005","volume":"30 12","author":"S Aharoni","year":"2020","unstructured":"Aharoni S, Nevo Y, Orenstein N, Basel-Salmon L, Ben-Shachar S, Mussaffi H, et al. Impact of a national population-based carrier-screening program on spinal muscular atrophy births. Neuromuscul Disord. 2020;30 12:970\u20134. https:\/\/doi.org\/10.1016\/j.nmd.2020.10.005.","journal-title":"Neuromuscul Disord"},{"key":"4774_CR30","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/s41436-020-0876-4","volume":"22 11","author":"AH Buchanan","year":"2020","unstructured":"Buchanan AH, Lester Kirchner H, Schwartz MLB, Kelly MA, Schmidlen T, Jones LK, et al. Clinical outcomes of a genomic screening program for actionable genetic conditions. Genet Med. 2020;22 11:1874\u201382. https:\/\/doi.org\/10.1038\/s41436-020-0876-4.","journal-title":"Genet Med"},{"key":"4774_CR31","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jpeds.2018.09.063","volume":"205","author":"MJ Chan","year":"2019","unstructured":"Chan MJ, Liao HC, Gelb MH, Chuang CK, Liu MY, Chen HJ, et al. Taiwan National Newborn Screening Program by Tandem Mass Spectrometry for Mucopolysaccharidoses Types I, II, and VI. J Pediatr. 2019;205:176\u201382. https:\/\/doi.org\/10.1016\/j.jpeds.2018.09.063.","journal-title":"J Pediatr"},{"key":"4774_CR32","doi-asserted-by":"publisher","unstructured":"Chien YH, Chiang SC, Weng WC, Lee NC, Lin CJ, Hsieh WS et al. Presymptomatic Diagnosis of Spinal Muscular Atrophy Through Newborn Screening. J Pediatr. 2017;190:124-9 e1. https:\/\/doi.org\/10.1016\/j.jpeds.2017.06.042.","DOI":"10.1016\/j.jpeds.2017.06.042"},{"key":"4774_CR33","doi-asserted-by":"publisher","first-page":"1074512","DOI":"10.3389\/fphar.2023.1074512","volume":"14","author":"HG Eichler","year":"2023","unstructured":"Eichler HG, Kossmeier M, Zeitlinger M, Schwarzer-Daum B. Orphan drugs\u2019 clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement. Front Pharmacol. 2023;14:1074512. https:\/\/doi.org\/10.3389\/fphar.2023.1074512.","journal-title":"Front Pharmacol"},{"key":"4774_CR34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1750-1172-6-42","volume":"6","author":"S Simoens","year":"2011","unstructured":"Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6:42. https:\/\/doi.org\/10.1186\/1750-1172-6-42.","journal-title":"Orphanet J Rare Dis"},{"key":"4774_CR35","doi-asserted-by":"publisher","unstructured":"de Andres-Nogales F, Cruz E, Calleja MA, Delgado O, Gorgas MQ, Espin J, et al. A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study). Orphanet J Rare Dis. 2021;16(1:186). https:\/\/doi.org\/10.1186\/s13023-021-01809-1.","DOI":"10.1186\/s13023-021-01809-1"},{"key":"4774_CR36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ejpn.2023.06.010","volume":"46","author":"J Huang","year":"2023","unstructured":"Huang J, Feng Y, Wang J, Huang S, Jin J, Xu L, et al. Feasibility analysis of intrathecal administration strategy of nusinersen based on Cobb angle in children with spinal muscular atrophy. Eur J Paediatr Neurol. 2023;46:55\u201360. https:\/\/doi.org\/10.1016\/j.ejpn.2023.06.010.","journal-title":"Eur J Paediatr Neurol"},{"key":"4774_CR37","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1377\/hlthaff.2023.00527","volume":"42 11","author":"C Horrow","year":"2023","unstructured":"Horrow C, Kesselheim AS. Confronting High Costs And Clinical Uncertainty: Innovative Payment Models For Gene Therapies. Health Aff (Millwood). 2023;42 11:1532\u201340. https:\/\/doi.org\/10.1377\/hlthaff.2023.00527.","journal-title":"Health Aff (Millwood)"},{"key":"4774_CR38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/brainsci13101419","volume":"13","author":"Y Qiao","year":"2023","unstructured":"Qiao Y, Chi Y, Gu J, Ma Y. Safety and Efficacy of Nusinersen and Risdiplam for Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Brain Sci. 2023;13:10. https:\/\/doi.org\/10.3390\/brainsci13101419.","journal-title":"Brain Sci"},{"key":"4774_CR39","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s40265-020-01410-z","volume":"80 17","author":"S Dhillon","year":"2020","unstructured":"Dhillon S, Risdiplam. First Approval Drugs. 2020;80 17:1853\u20138. https:\/\/doi.org\/10.1007\/s40265-020-01410-z.","journal-title":"First Approval Drugs"},{"key":"4774_CR40","doi-asserted-by":"publisher","first-page":"105278","DOI":"10.1016\/j.nmd.2025.105278","volume":"48","author":"S Corti","year":"2025","unstructured":"Corti S, Sansone V, Bitetti I, Brolatti N, Gadaleta G, Patanella AK, et al. Italian survey on evolving SMA care with disease-modifying therapies: a consensus workshop on nutrition, swallowing, respiratory and rehabilitation care. Neuromuscul Disord. 2025;48:105278. https:\/\/doi.org\/10.1016\/j.nmd.2025.105278.","journal-title":"Neuromuscul Disord"},{"key":"4774_CR41","doi-asserted-by":"publisher","unstructured":"Fauroux B, Griffon L, Amaddeo A, Stremler N, Mazenq J, Khirani S, et al. Respiratory management of children with spinal muscular atrophy (SMA). Arch Pediatr. 2020;27 7S. https:\/\/doi.org\/10.1016\/S0929-693X(20)30274-8. 7S29-7S34.","DOI":"10.1016\/S0929-693X(20)30274-8"},{"key":"4774_CR42","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/CM9.0000000000003049","volume":"137 10","author":"Y Feng","year":"2024","unstructured":"Feng Y, Wei J, Yao M, Jin J, Cui Y, Long Q, et al. Nutritional and lipid profile status of children with spinal muscular atrophy in China: A retrospective case-control study. Chin Med J (Engl). 2024;137 10:1243\u20135. https:\/\/doi.org\/10.1097\/CM9.0000000000003049.","journal-title":"Chin Med J (Engl)"},{"key":"4774_CR43","doi-asserted-by":"publisher","unstructured":"Zhang W, Feng Y, Yan Y, Yao M, Gao F, Lin W, et al. Health information literacy among children with spinal muscular atrophy and their caregivers. Ital J Pediatr. 2024;50(1:157). https:\/\/doi.org\/10.1186\/s13052-024-01723-9.","DOI":"10.1186\/s13052-024-01723-9"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-04774-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04774-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04774-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:00:45Z","timestamp":1781636445000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-04774-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4774"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-04774-z","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Declaration of Helsinki. The study protocol and the waiver of signed informed consent were approved by the Ethics Committee of the Children\u2019s Hospital, Zhejiang University School of Medicine (Reference No. 2024-IRB-0046). As an anonymous online survey, no personally identifiable information was collected, and participation was entirely voluntary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"219"}}